Dr. Everardo Saad joins Hemerion as Medical Director. The appointment of this expert in oncology clinical trials marks Hemerion’s entry into a new phase of clinical investigation, with the upcoming launch of a pivotal study dedicated to its Pentalafen® / Heliance® technology in the treatment of glioblastoma and the expansion of its pipeline to other oncology indications.
Dr. Everardo Saad is a medical oncologist by training and a fellow of the MD Anderson Cancer Center. He has over 25 years of experience in oncology and clinical research consulting, notably at IDDI, a world-class CRO.
He has co-authored nearly 100 scientific publications, notably on surrogate endpoints and biostatistics applied to clinical research, adaptive trials, and the method of generalized pairwise comparisons.
Appointed on October 1, 2025 on a part-time basis, Dr. Everardo Saad is tasked with guiding Hemerion’s clinical development in its two major markets: Europe and the United States.
Having contributed to the design or analysis of more than 100 clinical trials, he brings to Hemerion all the expertise necessary to effectively implement and manage the pivotal clinical phase of validation of the Pentalafen®/Heliance® combination therapy for the treatment of glioblastoma in Europe and the United States.
He advises and guides Hemerion’s clinical and regulatory affairs teams on compliance strategy, protocol development and implementation, and data collection and analysis for FDA and EMA submissions.
With this appointment, Hemerion is strengthening its ability to rapidly ramp up the clinical development of its first therapy and begin market access operations. The goal is to bring the Pentalafen®/Heliance® combination therapy to market in 2030.